TP53 and familial pancreatic carcinoma: The ATR inhibitor VE-822 (Vertex Pharmaceuticals, USA), has been reported to radio-sensitise p53-mutated pancreatic cancer cell lines in vitro and in xenograft models of human pancreatic cancer and further increases the growth delay induced by ionising radiation (IR) combined with gemcitabine.